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ApoptosisWe have previously reported that rhomboid domain containing 1 (RHBDD1), a new member of the
Rhomboid family, is highly expressed in testis. In the present work, luciferase analyses showed that
RHBDD1 enhanced the AP-1 activity in a dose- and activity-dependent manner. RHBDD1 overexpres-
sion increased c-Jun activity, and the activity was visibly inhibited when RHBDD1 was knocked
down. The suppression of c-Jun by inactivation of RHBDD1 was rescued by overexpressing RHBDD1.
However, c-Jun overexpression did not alter the expression level of RHBDD1. Furthermore, knock-
down of RHBDD1 led to increased cell apoptosis and reduced expression of Bcl-3. Our ﬁndings indi-
cate that RHBDD1 could inhibit cell apoptosis by activating and upregulating c-Jun and its
downstream target, Bcl-3.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Rhomboids, widely distributed throughout the living world, are
polytopic membrane proteins that play a critical role as the prote-
ases responsible for several processes including the following: the
activation of EGFR signalling in Drosophila [1,2], the regulation of
mitochondrial membrane remodelling [3–5], the activation of pro-
tein translocation in bacteria [6], the host invasion by the malaria
parasite and related intracellular parasites [7–9] and the immune
system evasion by parasitic amoeba [10]. Genomic studies have
found that Rhomboid proteins represent a highly conserved mem-
brane protein family across kingdoms [11]. The human genome
contains several Rhomboid-like genes that can be phylogenetically
grouped into three major classes [12]. The ﬁrst class includes the
true active Rhomboid genes that are subdivided into the secretase
(e.g., RHBDL-1/-2/-3) and PARL-type subfamilies. The second class
is composed of novel inactive Rhomboid members and was re-
cently named the iRhoms group (e.g., RHBDF-1/-2 genes). The third
class includes a small number of other distant evolutionarily re-
lated and uncharacterised genes (e.g., RHBDD-2/-3) for which there
is no evidence to show that they are active proteases. RHBDD1, as a
new member of the Rhomboid family, plays a biological role by
digesting different substrates such as the tumour suppressor acti-
vated pathway-6 (TSAP6) or the pro-apoptotic protein Bik [13,14].The AP-1 (activator protein 1) transcription factor is a dimeric
complex that comprises members of the JUN, FOS, ATF (activating
transcription factor) and MAF (musculoaponeurotic ﬁbrosarcoma)
protein families [15]. AP-1 transcription factors have also been
implicated in the control of cell death and survival, and the conse-
quence of AP-1 activation seems to be cell type speciﬁc. It is re-
ported that AP-1 induces apoptosis in the nervous system, and it
blocks apoptosis in IL-4-deprived T cells by upregulating the
expression of an anti-apoptotic protein, Bcl-3 [16]. The different
functions of AP-1 in the regulation of cell apoptosis could be ex-
plained by the regulation of different downstream target genes.
In the present study, we investigated the biological effects of
RHBDD1 on apoptosis. Our observations indicated that RHBDD1,
but not the mutant RHBDD1 (S144A) or RHBDL2, could induce
the speciﬁc activation of AP-1. Endogenous c-Jun activity de-
creased when RHBDD1 was knocked down, and RHBDD1 func-
tioned as an antiapoptotic protein by regulating Bcl-3, which is
the downstream target of AP-1. These results will facilitate further
insight into the biological and molecular functions of RHBDD1 in
cancer.
2. Materials and methods
2.1. Cell culture, plasmids and transfection
Cell lines were obtained from the Cell Resource Center in Peking
Union Medical College (PUMC). HeLa and HEK 293T cells were
Fig. 1. RHBDD1 increases the activity of AP-1. (A) RHBDD1 overexpression activated the AP-1 signal pathway by luciferase assay. Reporter genes were transfected into HEK
293T cells, and the cells were extracted after 24 h to undergo luciferase assays. (B) RHBDD1 increased the activity of AP-1 in a dose-dependent manner. HEK 293T cells were
co-transfected with an AP-1-driven luciferase reporter and different amounts of RHBDD1. The relative luciferase activity was measured. (C) RHBDD1 could activate AP-1
speciﬁcally. HEK 293T cells were co-transfected with either an AP-1-driven luciferase reporter, RHBDD1 or the control vectors. Relative luciferase activity was measured. (D)
RHBDD1 knockdown HeLa cells were analysed by luciferase assay. The lower panel indicates the knockdown of RHBDD1, and a-Tubulin was analysed as a loading control. The
luciferase activity of each condition was normalised to a co-transfected pRL-TK vector. A representative example of at least three independent experiments, performed in
triplicate, is shown. The error bars indicate the standard deviation.
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bovine serum (FBS); RKO cells were cultured in IMDM (HyClone;
Thermo Scientiﬁc) with 10% FBS in 5% CO2 incubators at 37 C.
Adherent cells were passaged every 2–3 days with 0.5 mg/ml tryp-
sin (1:250) and 0.53 mM ethylenediaminetetraacetic acid (EDTA).
Expression plasmids for RHBDD1 and RHBDL2 were cloned into
pcDNA6.0 with a C-terminal Myc tag. An RNAi oligo against
RHBDD1 was cloned into the pSilencer-1.0-U6 (the sense and anti-
sense primers were GATTCTTGTTGGACTAATTTCAAGAGAATTAGTC
CAACAAGAATCCTTTT TG and AATTCAAAAAGGATTCTTGTTGACTAA
TTCTCTTGAAATTAGTCCAACAAGAA TC, respectively). The plasmids
were constructed according to standard cloning techniques. All
point mutants were generated using the Molecular Cloning Meth-
od. One chimera, S144A was constructed by replacing serine144
with alanine. The plasmid transfections were performed using
Lipofectamine™ 2000 (Invitrogen, CA).
2.2. Luciferase assays
The pAP1-Luc plasmid (Stratagene) was transfected into HEK
293T cells using Lipofectamine™ 2000. In addition, HEK 293T cells
were cotransfected with a Renilla luciferase control vector (Prome-
ga) to monitor the transfection rates. Fireﬂy and Renilla luciferase
activities were measured using the Dual-Luciferase Reporter Assay
System (Promega). Brieﬂy, the cells were washed with PBS and
lysed with passive lysis buffer. Cell lysates were mixed with Lucif-
erase Assay Reagent II, and the Fireﬂy luminescence was measured
using a luminometer (TD-20/20, Turner BioSystems, USA). Next,
the samples were mixed with the stop reagent, and Renilla lucifer-
ase activity was measured as an internal control. Relative lucifer-
ase activity was calculated as the ratio of Fireﬂy luciferase
activity to Renilla luciferase activity.2.3. Antibodies
The RHBDD1 mouse monoclonal antibody was prepared in our
laboratory. The Bcl-3 antibody was purchased from Santa Cruz Bio-
technology. Other antibodies used in this study were phospho-c-
Jun (Ser63) (Cell Signaling Technology, 9261S), phospho-c-Jun
(Ser73) (Cell Signalling Technology, 9164S), Bcl-xL (Cell Signaling
Technology, 2764), c-Jun (BD Pharmingen, 610326), PARP (Cell Sig-
naling Technology, 9542S) and GAPDH (Zhongshanjinqiao, Beijing,
CN). HRP-conjugated secondary antibodies were applied from San-
ta Cruz Biotechnology.
2.4. Western blot
Proteins were extracted with SDS lysis buffer (50 mM Tris–HCl
[pH 6.8], 10% glycerol, and 2% SDS) and quantiﬁed using the BCA
protein assay reagent (Thermal). Extracts were loaded in a 12%
SDS–PAGE gel, separated and then electrophoretically transferred
to a PVDF membrane (GE Healthcare). The membrane was blocked
in 5% skim milk for 1 h at room temperature and then incubated
overnight with the indicated antibodies at 4 C. The membrane
was incubated with an anti-rabbit or an anti-mouse HRP-IgG (San-
ta Cruz) for 1 h at room temperature. Chemiluminescence was de-
tected using an ECL blot detection system (Santa Cruz).
2.5. Flow cytometric analysis
Cells were exposed to 40 J/m2 UV to induce apoptosis. FITC-
Annexin V kit, NeoBioscience was used to stain cells according
to the manufacturer’s instructions. Apoptotic cells were analysed
with a BD Accuri C6 Flow Cytometer and corresponding CellFIT
software.
Fig. 2. RHBDD1 increased the activity of endogenous c-Jun. (A) RHBDD1 overexpression increased c-Jun expression. HEK 293T cells were transfected with the Myc-tagged
wild type RHBDD1(RHBDD1 wt-Myc), mutant RHBDD1 (RHBDD1 mt-Myc), and the control vector, respectively. The cells were extracted after 24 h for Western blot analysis
using the indicated antibodies. (B) HeLa cells were analysed using the methods described in A. (C) c-Jun expression was supressed when RHBDD1 was knocked down. The
HeLa cells with RNAi-knocked down RHBDD1 were harvested for Western blot analysis. (D) Expression of the AP-1 proteins in RHBDD1-wt and RHBDD1-mt RKO cells was
examined by Western blotting. (E) Suppression of c-Jun by inactivation of RHBDD1 was rescued by overexpressing RHBDD1. RKO-mt cells were transfected with RHBDD1-
Myc, S144A-Myc and control vector, respectively. The cells were extracted after 24 h for Western blot analysis using the indicated antibodies.
Fig. 3. The RHBDD1 expression was not affected by the activity of c-Jun. (A) c-Jun did not alter RHBDD1 expression. HEK 293T cells were transfected with either c-Jun or a
control vector. The cells were extracted after 24 h and 36 h for Western blot analysis using the indicated antibodies. (B) The procedure described in A was also performed in
HeLa cells.
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3.1. RHBDD1 overexpression induced AP-1 activation in a dose- and
activity-dependent manner
To investigate whether RHBDD1 could regulate the signalling
pathway process, we performed reporter gene analyses in HEK293T cells using luciferase assays. As shown in Fig. 1A, RHBDD1
overexpression markedly activated the AP-1 pathway, and it en-
hanced AP-1 activity in a dose-dependent manner (Fig. 1B). When
the serine at codon 144, which is the key amino acid of the
RHBDD1 protease as proved by our previous work [13], was re-
placed with alanine, the mutant (S144A) could not activate AP-1
(Fig. 1C). RHBDL2, a mammalian rhomboid protease with several
Fig. 4. RHBDD1 inhibits UV-induced apoptosis by upregulating Bcl-3 expression. (A) Annexin V/PI FACS assay to analyse apoptosis in RHBDD1 knockdown HeLa cells after UV
irradiation. The percentage of apoptotic cells (% of total cells), including early apoptotic cells (Annexin V+, PI) and late apoptotic cells (Annexin V, PI+), is shown as a bar
graph. The data are representative of three different experiments, and the error bars represent the standard deviations of triplicate samples. (B) After UV irradiation, the
RHBDD1 knockdown HeLa cells were extracted at the indicated time points for Western blot analysis. (C and D) The RHBDD1-wt and RHBDD1-mt RKO cells were treated
using the methods described in A and B.
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results indicated that RHBDD1 could activate AP-1 speciﬁcally. In
accordance with the above results, the AP-1 activity decreased
when RHBDD1 was knocked down in HeLa cells (Fig. 1D). Taken to-
gether, these results suggested that RHBDD1 could speciﬁcally
activate the AP-1 pathway.
3.2. RHBDD1 increased endogenous c-Jun activity
c-Jun, the most extensively studied protein of the activator pro-
tein-1 (AP-1) complex, is involved in numerous cell activities such
as proliferation, apoptosis, survival, tumorigenesis and tissue mor-
phogenesis [20]. To further deﬁne the mechanism of AP-1 activa-
tion by RHBDD1, the distribution and phosphorylation status of
the endogenous c-Jun were examined. Myc-tagged RHBDD1 wild
type (RHBDD1-Myc), RHBDD1 mutant (S144A-Myc) and a control
vector was respectively transfected into HEK 293T or HeLa cells;
then, the cells were harvested after 24 h. As shown in Fig. 2A and
B, RHBDD1 overexpression increased c-Jun expression signiﬁ-
cantly. Additionally, the phosphorylation of both Ser-63 and Ser-
73 of c-Jun was elevated when RHBDD1 was overexpressed.Accordingly, the increase in c-Jun expression was inhibited when
RHBDD1 was knocked down (Fig. 2C). When we used the targeted
knock-in RKO cells (RKO-mt) in which RHBDD1 had been endoge-
nously inactivated, as shown in Fig. 2D, the expression and activa-
tion of c-Jun decreased dramatically, compared with the wild type
RKO cells (RKO-wt) (Fig. 2D). To further conﬁrm whether the sup-
pression of c-Jun was due to inactivation of RHBDD1, we transfec-
ted RHBDD1-Myc, S144A-Myc and a control vector into RKO-mt
cells, respectively. The cells were harvested after 24 h, and Wes-
tern blot was performed to determine the expression of c-Jun. As
shown in Fig. 2E, compared with the control and S144A, the activ-
ity and phosphorylation of c-Jun was rescued when RHBDD1 was
overexpressed in RKO-mt cells.
3.3. RHBDD1 expression was not affected by the activity of c-Jun
Based on the experimental data showing that RHBDD1 en-
hanced c-Jun activity, we hypothesised that RHBDD1 might be af-
fected by the feedback regulation of c-Jun. To test this hypothesis,
either c-Jun or a control vector was transfected into HEK 293T and
HeLa cells, and the cells were harvested after 24 and 36 h. A
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sults demonstrated that the expression level of RHBDD1 did not
change when c-Jun increased visibly (Fig. 3A and B). Therefore,
RHBDD1 enhanced the AP-1 activity, whereas c-Jun did not alter
RHBDD1 expression.
3.4. RHBDD1 inhibits cell apoptosis by upregulating Bcl-3 expression
Given that several studies identiﬁed c-Jun as a key regulator of
UV-mediated apoptosis [21–23] and an AP-1 binding site was
identiﬁed in the Bcl-3 promoter [24], we investigated whether
the anti-apoptotic role of RHBDD1 could be related to a differential
activation of Bcl-3 via c-Jun regulation. We exposed target cells to
UV irradiation and harvested them at the indicated time points.
Apoptosis was measured by FACS analysis. The results showed that
either the RHBDD1 knockdown or its endogenous inactivation
induced apoptosis signiﬁcantly, compared to the control cells
(Fig. 4A and C). Inhibition of apoptosis by AP-1 is most likely due
to the differential regulation of pro-apoptotic and anti-apoptotic
target factors [25,26]. Therefore, we observed the effect of RHBDD1
on Bcl-3, Bcl-2, Bcl-xL and Bax. A Western blot analysis revealed
that the activity and expression of c-Jun and Bcl-3 were suppressed
after UV irradiation when RHBDD1 was knocked down or endoge-
nously inactivated. However, RHBDD1 did not affect the expression
of Bcl-xL, Bcl-2 or Bax under the same conditions (Fig. 4B and D).
We also measured poly (ADP-ribose) polymerase (PARP) and
cleaved caspase 7 to evaluate the effect of the RHBDD1 knockdown
or mutation on apoptosis after UV stimulation. When compared
with the control samples, the level of PARP and cleaved caspase
7 increased when RHBDD1 was knocked down (Fig. 4B and D), sug-
gesting that RHBDD1 has an anti-apoptotic effect when cells are
exposed to UV. Taken together, the above ﬁndings suggested that
RHBDD1 exerted its anti-apoptotic effect by activating AP-1 activ-
ity, which then upregulated the expression of Bcl-3.
4. Discussion
Rhomboids comprise a family of intramembrane serine prote-
ases that catalyse the cleavage of transmembrane segments within
the lipid membrane to achieve a wide range of biological functions.
The presence of Rhomboid proteins throughout the living world
implies that they are unusually useful factors that originated early
in the evolution of life and have been conserved [27]. RHBDD1, a
gene that is highly expressed in human testis, was identiﬁed as a
novel member of the Rhomboid family of serine proteases because
of the following four characteristics: its highly-conserved Rhom-
boid domain, its ability to cut substrates at the GG motif, its sensi-
tivity to a speciﬁc serine protease inhibitor, and its GFSGV motif
[13]. Most research on RHBDD1 has focused on that RHBDD1 could
induce the cleavage of different substrates to involve in many bio-
logical processes [13,14]. In the present work, by screening several
pathways using luciferase assays, we proved that RHBDD1 could
increase the activity of AP-1 in a dose-dependent manner. Immu-
noblotting results also supported this conclusion by showing that
knocking down RHBDD1 decreased endogenous c-Jun activity. Fur-
thermore, the inhibition of c-Jun by RHBDD1 depletion was res-
cued by RHBDD1 overexpression. This is the ﬁrst time that a
Rhomboid protein is shown to be able to regulate the activity of
AP-1.
The AP-1 transcription factor regulates some target factors that
have putative roles in tumour cell proliferation and apoptosis [15].
JUN proteins preferentially regulate genes that are implicated in
proliferation and apoptosis, such as CD44 [28], Bcl-3 [29] and cy-
clin D1 [30], whereas FOS proteins are often required for angiogen-
esis and invasion by malignant tumours, such as DNMT1 [31],VEGFD [32] and MMP1 [33]. It is interesting to observe that the
growth speed of RKO colorectal cancer cells slowed down when
RHBDD1 was knocked down, and we supposed that the change
could be related to the cell cycle and to apoptosis. To clarify this
assumption, Bcl-3 and cyclin D1 were selected as targets of re-
search. The Western blot analysis indicated that RHBDD1 en-
hanced the expression level of Bcl-3 after UV exposure. To
provide more evidence to support previous results, the data from
ﬂow cytometric analysis showed that RHBDD1 could inhibit cell
apoptosis. However, RHBDD1 overexpression could also increase
cyclin D1, as detected by Western blot, while RHBDD1 suppression
did not alter the release from the G1 to S phase after the cells were
synchronised at the G1 phase (data not shown). Consequently, the
low growth of RHBDD1-mt cells is due to the apoptosis induced by
the RHBDD1 knockdown, instead of a cell cycle block.
Apoptosis is a complicated process characterised by its mor-
phology and biochemical mechanism, andmany key apoptosis pro-
teins have been identiﬁed [34]. The control and regulation of
apoptotic mitochondrial events occur through members of the
Bcl-2 family of proteins [35]. A total of 25 factors have been iden-
tiﬁed in the Bcl-2 family, including Bcl-2, Bcl-xL and Bim. A study
suggested that Bcl-3 could replace the antiapoptotic role of Bcl-2
and Bcl-x in TS1ab cells [16]. It is proposed that Bcl-3 overexpres-
sion has contributed to the development of chronic lymphocytic
leukaemia through the downregulation of genes that are important
for cell proliferation and differentiation [36,37]. Furthermore, the
AP-1 binding sites were critical in the Bcl-3 promoter activation,
and their mutations abrogate the promoter’s activity. The JUN pro-
teins, which are involved in the formation of AP-1 transcription
factors, play an important role in the IL-4-induced Bcl-3 expression
[16]. Several studies have indicated that the c-Jun activation may
be critical as a determinant of the functional outcome of the stress
response, especially UV-induced cell death, so cell apoptosis was
induced by UV irradiation in our experiments. The immunoblotting
assays indicated that apoptotic cells increased and the cleaved
PARP, caspase 7 were enhanced after UV irradiation. Accordingly,
the increase of Bcl-3 was inhibited when c-Jun expression was re-
duced. Besides, other pro-apoptotic and anti-apoptotic factors,
such as Bcl-2, Bcl-xL and Bax have not been affected by RHBDD1.
Taken together, RHBDD1 regulated cell apoptosis by activating
the downstream target of AP-1, Bcl-3.
In summary, our results demonstrate that RHBDD1 is an anti-
apoptotic protein that could inhibit cell apoptosis by upregulating
the activity and expression of AP-1 and its target, Bcl-3. It is novel
to determine that the AP-1 pathway is involved in RHBDD1-regu-
lated apoptosis, and we wonder whether it may have possible
crosstalk with other signalling pathways. The ability of RHBDD1
to modulate cell apoptosis is recognised for its immense therapeu-
tic potential, and further studies exploring the potential applica-
tions of RHBDD1 may be beneﬁcial to cancer therapy.
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